Le medicament du mois. Etoricoxib (Arcoxia)

Anti-Inflammatory Agents, Non-Steroidal; Isoenzymes; Membrane Proteins; Pyridines; Sulfones; Cyclooxygenase 2; etoricoxib; Prostaglandin-Endoperoxide Synthases

Abstract :

[en] Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60, 90 and 120 mg are available. The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis. Etoricoxib's efficacy has been widely studied in comparative studies, showing the same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects.

Disciplines :

Rheumatology

Author, co-author :

Leclercq, P.

Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie

Language :

French

Title :

Le medicament du mois. Etoricoxib (Arcoxia)

Alternative titles :

[en] Etoricoxib (Arcoxia)

Publication date :

2004

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

345-349

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 19 September 2010

Statistics

Number of views

345 (5 by ULiège)

Number of downloads

909 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Brooks P, Emery P, Evans JF, et al.- Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 1999, 38, 779-88.
Riendeau D, Percival MD, Brideau C, et al.- Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001, 296 (2), 558-66
Patrignani P, Tacconelli S, Capone ML, et al.- The selectivity of novel COX-2 inhibitors in human whole blood assays of COX-isozyme activity [abstract]. EULAR 2002 Annual European Congress of Rheumatology; 2002 12-15 Jun; Stockholm.
Leung AT, Malmstrom K, Gallacher AE, et al.- Efficacy and tolerability profile of etoricoxib: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002, 18 (2), 49-58.
Dallob A, Deprè M, De Lepeleire I et al.- MK-0663, a highly selective inhibitor of COX-2 in humans. Ann Rheum Dis 2000, 59 (suppl. 1):331.
Wagner JA, Kraft W, Burke J, et al.- The COX-2 inhibitor etoricoxib did not alter the anti-platelet effects of low-dose aspirin in healthy volunteers [abstract no. 498]. Arthritis Rheum 2001, 44 (Suppl.) (9), S135
De Lepeleire I, Dallob A., Gerrits M et al.- Biochemical activity, safety and pharmacokynetics after multiple doses of MK-0663, a COX-2 specific inhibitor, in healthy volunteers. VII World Conference of Clinical Pharmacology and Therapeutics IUPHAR. Florence, Italy (2000) 456.
Agrawal NGB, Porras AG, Matthews CZ et al.- Dose proportionality of oral etoricoxib, a highly selective COX-2 inhibitor, in headline volunteers. J Clin Pharm 2001, 41, 1006-1110.
Hunt RH, Bowen B, James C et al.- COX-2 specific inhibition with MK-0663 120 mg q.d. over 4 weeks did not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg t.i.d [abstract no. 3031]. Gastroenterology 2001, 120 (Suppl. 1) (5), 597
Chauret N, Yergey JA, Brideau C et al.- In vitro metabolism consideration, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001, 11, 1059-62.
Merck Sharp & Dohme Limited.- Arcoxia (etoricoxib) tablets: summary of product characteristics. 2002.
De Lepeleire I, Gottesdiener K, Shahane A, et al.- MK-0663 (a COX-2 inhibitor) did not affect prednisolone/prednisone plasma levels in healthy volunteers [abstract no. 455]. 7th World Conference on Clinical Pharmacology and Therapeu-tics and the 4th Congress of the European Association for Clinical Pharmacology and Therapeutics, 2000 15-20 Jul; Florence, 118.
Wagner JA, Agrawal NGB, Guillaume M, et al.- Lack of effect of antacids on single-dose pharmacokinetics of MK-0663 [abstract no. 110]. Clin Pharmacol Ther 2001, 69 (Suppl.) (2), 60.
Patrignani P, Capone ML, Tacconelli S.- Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin Pharmacother 2003, 4, 262-83.
Cochrane DJ, Jarvis B and Keating GM. Etoricoxib. Drugs 2002, 62(16), 1-15.
Kassahun K, Mc Intosh IS, Shou M et al.- Role of human liver cytochrome P450 3A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001, 29 (6), 813-20
Tang C, Shou M, Mei Q et al.- Major role of human liver microsomal cytochrome P450 2C9 in the oxydation métabolisme of celecoxib, a novel COX-2 inhibitor. J Pharmacol Exp Ther 2000, 298, 453-459.
Hamman MA, Thompson GA, Hall SD.- Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Phar 1997, 54, 33-41.
Gottesdiener K, Schnitzer T, Fisher C et al.- Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002, 41(9), 1052-61.
Curtis SP, Maldonado-Cocco J, Lozada B et al.- Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis [abstract no. 955]. Arthritis Rheum 2000, 43(Suppl.), 226
Matsumoto AK, Melian A, Mandel DR, et al.- A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002, 29 (8), 1623-30
Collantes E, Curtis SP, Lee KW et al.- A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002, May 22, 3 (1), 10.
Schumacher HR Jr, Boice JA, Daikh DI, et al.- Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002 Jun 22, 324 (7352), 1488-92.
Malmstrom K, Shahane A, Fricke JR, et al.- MK-0663, an investigational COX-2 inhibitor: the effect in acute pain using the dental-impaction model [abstract no. 1393]. Arthritis Rheum 2000, 43 (Suppl.) (9), 299
Malmstrom K, Kotey P, Coughlin H, et al.- Efficacy of etoricoxib, naproxen sodium, and acetaminophen/codeine in acute dental pain. Clin Pharmacol Ther 2001, 69 (Suppl.)(2), 2
Malmstrom K, Kotey P, Cichanowitz N, et al.- The effect of etoricoxib, a highly selective COX-2 inhibitor, in primary dysmennorrhea: a randomized, double-blind, crossover study [abstract no. 783]. J Pain 2002, 3 (Suppl.), 46.
Geba GP, Seger W, Adler JL, et al.- Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: a 3 month placebo-controlled trial [abstract]. EU-LAR 2002 Annual European Congress of Rheumatology, 2002 12-15 Jun, Stockholm
Geba G, Puopolo A, Birbara C, et al.- Treatment of chronic low back pain (LBP) with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: a three-month placebo-controlled trial [abstract no. 647]. J Pain 2002, 3 (Suppl. 1), 12.
Curtis SP, Lee M, Ng J, et al.- Fewer upper-GI perforations, ulcers and bleeds (PUBS) with etoricoxib than with nonselective cyclooxygenase inhibitors (NSAIDS) [abstract]. EULAR 2002 Annual European Congress of Rheumatology, 2002 12-15 Jun
Zacher J, Feldman D, Gerli R et al.- A comparison of the therapeutic efficacy and tolerability of etoricoxib and dictofenac in patients with osteoarthritis. Curr Med Res Opin. 2003, 19, 725-36.
Curtis SP, Braunstein N, Sperling R, et al.- Renovascular safre profile of etoricoxib [abstract and poster]. EULAR 2002 Annual European Congress of Rheumatology; 2002 12-15 Jun, Stockholm.